anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including ACEON) may be subject to a variety of adverse events, some of them serious. Black patients receiving ACE inhibitors have a higher incidence of angioedema compared to nonblacks.

Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis, or larynx has been reported in patients treated with ACE inhibitors, including ACEON (0.1% of patients treated with ACEON in U.S. clinical trials). Angioedema associated with involvement of the tongue, glottis or larynx may be fatal. In such cases, discontinue ACEON treatment immediately and observe until the swelling disappears. When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, administer appropriate therapy, such as subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL), promptly.

Intestinal Angioedema: Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.
174,471. Cohen, N. Nov. 9, 1920. Teeth, artificial. - A composition for making dentures comprises a mixture of powdered vulcanized rubber sufficiently pure to be used for dental purposes, and ordinary unvulcanized dental or similar rubber, preferably in equal proportions, with or without sulphur as required. Dentures may be directly modelled with the teeth in position, and tested in the mouth prior to vulcanization. The material may also be used for the repair of dentures, or it may be used instead of the wax described in Specification 112,860.
PURPOSE:To provide a feed additive having high safety and excellent effect to promote the growth of cattle, poultry, fish, etc. and to improve the feed efficiency, etc., by using trialkyl(2-hydroxyalkyl)ammonium carboxylate as an essential component, and to provide a feed containing said feed additive. CONSTITUTION:The objective feed additive is composed of the compound of formula I (group of formula II is 6-24C fatty acid anion; R<1>-R<3> are lower alkyl; R<4>-R<7> are H or lower alkyl), especially trimethyl(2-hydroxyethyl)ammonium carboxylate. The additive is added to a raw material of feed in an amount of preferably 0.01-10wt%, especially about 0.02-5wt% to obtain the final product. The above compound is effective to promote the digestion and absorption of various nutrients of feed and improve its utilization efficiency, and accordingly, comparable or higher growth of animals can be achieved even by the use of a feed having lower nutrient level than the conventional feed. The feed additive has absolutely no safety problems.
The present invention provides a production method for recombinant cytoglobin and a use of the cytoglobin. Cytoglobin is a new member of a six-element globulin family (hxHb) expressed by the mechanocytes of various kinds of tissue. The cytoglobin to which the present invention relates to comprises recombinant human cytoglobin, recombinant rat cytoglobin and recombinant mice cytoglobin. The cytoglobin to which the present invention relates to can be clinically used for promoting the growth of the skin tissue, and the epithelial tissue of the cornea, the stomach, the lung and the air pipe, decelerating senescence, resisting oxidation and inflammation, and accelerating the wound surface healing of burn, scalds and ulcers, and wound healing after the organ tissue is excised. In the technical field of cosmetics, the cytoglobin can directly participate in the biological effect of skin metabolism, and promote the functions of nutrition restoring film-forming, adjustment, etc. of the skin. The functions of resisting oxidation, inflammation and ageing of the cytoglobin have the beauty treatment effects of skin cleaning and protection.
Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
OBJECTIVE: Bariatric surgery is an effective treatment to obesity, leading to weight loss and improvement in glycemia, that is characterized by hypersecretion of gastrointestinal hormones. However, weight regain and relapse of hyperglycemia are not uncommon. We set to identify mechanisms that can enhance gastrointestinal hormonal secretion following surgery to sustain weight loss.
METHODS: We investigated the effect of somatostatin (Sst) inhibition on the outcomes of bariatric surgery using a mouse model of sleeve gastrectomy (SG).
RESULTS: Sst knockout (sst-ko) mice fed with a calorie-rich diet gained weight normally and had a mild favorable metabolic phenotype compared to heterozygous sibling controls, including elevated plasma levels of GLP-1. Mathematical modeling of the feedback inhibition between Sst and GLP-1 showed that Sst exerts its maximal effect on GLP-1 under conditions of high hormonal stimulation, such as following SG. Obese sst-ko mice that underwent SG had higher levels of GLP-1 compared with heterozygous SG-operated controls. The SG-sst-ko mice regained less weight than controls and maintained lower glycemia months after surgery. Obese wild-type mice that underwent SG and were treated daily with a Sst receptor inhibitor for two months had higher GLP-1 levels, regained less weight, and improved metabolic profile compared to saline-treated SG-operated controls, and compared to inhibitor or saline-treated sham-operated obese mice.
CONCLUSIONS: Our results suggest that inhibition of Sst signaling enhances the long-term favorable metabolic outcomes of bariatric surgery.
Chronic kidney disease (CKD) causes skeletal muscle wasting, resulting in reduced function and inability to live independently. This systematic review critically appraised the scientific literature regarding the effects of full-body resistance training on clinically-relevant functional capacity measures in CKD. The study population included studies of people with Stage 4 or 5 CKD and a mean age of 40+ years old. Eight databases were searched for eligible studies: Pubmed, Embase, Cochrane, CINAHL, Scopus, Web of Science, MEDLINE, and AGELINE. MeSH terms and keyword combinations were used for screening following the PRISMA conduct. Inclusion criteria were based on PICO principles and no date of publication filter was applied. The intervention was training 2 days/week of structured resistance exercises using major upper and lower muscle groups. Minimum intervention period was 7 weeks. Comparison groups maintained their habitual activity without structured exercise training. Outcome measures of interest were: 6-min walk test, grip strength, timed up-and-go test, and sit-to-stand. Eight randomized controlled trials and one nonequivalent comparison-group study fulfilled the inclusion criteria and underwent data extraction. All studies were of hemodialysis patients. The evidence indicates that full-body resistance exercise significantly improved grip strength, timed up and go and sit to stand tests; metrics associated with enhanced quality and quantity of life.
This study aims to culturally adapt the existing Motivational Interviewing with CBT (MICBT) and integrate this with Mindfulness-Based Relapse Prevention (MBRP) intervention for people with SUD and to test the feasibility, and acceptability of the intervention in a randomized control trial (RCT). First phase will be cultural adaptation of intervention through focus groups and individual interviews with key stakeholders . Phase two will be to test integrated MICBT and MBRP on a small group of participants N=12.

Third phase will be a feasibility factorial randomized control trial with 260 participants with SUD (n=65). Participants will be recruited from primary care hospitals and drug rehabilitation centers in Karachi, Lahore, Rawalpindi, Hyderabad, and Peshawar Pakistan. Intervention will take place weekly over a period of 12 weeks. The intervention will consist of individual as well as group sessions. Assessments will be completed at baseline, after completion of intervention (12th week) and 24th week post randomization. All assessments will be administered by masked research assistants (RAs), not involved in delivering intervention sessions. The therapists delivering the intervention will be trained and will be provided ongoing supervisions by a senior therapist.
For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material. Before the commencement of the study, the participants will be asked for their phone number in the respondent sheet and permission will be sought from both participants and their teachers and parents/guardians. Then, a WhatsApp group will be created consisting of the selected participants for this intervention. The participants in WhatsApp group will further receive WhatsApp instant messages. These participants will grouped and placed in class. These messages will be sent in both Malay and English language. The duration of the session will be around 60-90 minutes. Pre-assessment will be taken prior to the dissemination of oral health education on WhatsApp. Post assessment will be taken afterwards to assess the oral health knowledge, practise and attitude.
This single-center, prospective, randomized, double-blind, controlled pilot study conducted at San Antonio Military Medical Center will evaluate the effectiveness of topical voriconazole for pain relief at autogenous skin donor sites compared to a topical placebo application. The patients will act as their own control. All participants and investigators in the study will be blinded to the treatment arm utilized on each of the patient's donor sites (voriconazole versus placebo). Patients, who are scheduled for skin grafting and have met the inclusion criteria for this study, will be invited to enroll in the study. Only those patients who have been planned for skin graft sites that are approximately symmetrical in size will be allowed to enroll in the study. The donor site wounds will be studied using a paired design consisting of voriconazole or the placebo applied topically to same-patient matched donor sites. Patients will be queried via the pain assessment tool as to perceived pain at timed intervals. Dialysate samples will be collected via microdialysis probes at matching timed intervals in order to measure levels of oxidized linoleic acid metabolites shown in previous studies to be present in peripheral nerves.
The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection.
The application or the online module will play a short didactic explanation video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures. It is currently unknown which method will be used, the online module or the application for the purpose. The study participants will be subjected to only one method (once the method have been finalized and created). The video content will engulf information about cervical, breast, colorectal and lung cancer prevention and early detection. After the video, the application or the module will capture information on gender, age, smoking status, body mass index and positive cancer history in family. Watching the video and answering the questions will take approximately 5 minutes. The study participants will download the application on their personal cell phones and the data collected will be linked to identifying information in case they choose to receive the compensation and opt for the 6-month follow-up. Based on the responses provided, and the age and the gender, the participants will be provided with a list of cancer prevention and early detection measure(s). A subset of the study participants from ARResearch (only those who have agreed for the 6-month follow-up) will be asked if they are willing to be contacted by the study staff after 6 ±1 months (from the date of enrollment in the study) to enquire if they received/adopted the screening measures(s) that were suggested based on their age, gender and family history. They will be asked whether it is OK to call and/or e-mail them for more information to better describe barriers to obtaining cancer prevention and screening measures.
Systems and methods facilitate information sharing among a plurality of member institutions. Each member is associated with a member number and a corresponding member profile. A member contributes its data relating to small business entities to an exchange repository upon becoming a member, and thereafter on a periodic basis. Each member is eligible to query against the exchange repository. However, a response to a member's inquiry is determined by a reciprocity due to the inquiring member. Each business entity regarding which information is stored in the exchange repository is associated with a business entity identifier. A business entity identifier associates a record file for the corresponding small business entity. The record file includes trade data of the small business, data relating to one or more principals of the small business entity, as well as data relating to one or more guarantors of the small business entity, as appropriate.
BACKGROUND: This study aimed to investigate the association between genetic variants of ERAP1 (OMIM: 606832) and psoriasis vulgaris (PsV) susceptibility in Inner Mongolia Han nationality.
METHODS: For primary screening, the subjects included 142 PsV cases and 100 healthy controls without psoriasis. The 27 exons of ERAP1 gene were sequenced to screen significant genetic variants. For the validation study, the subjects included 1030 PsV cases and 965 healthy controls. A total of 18 mutations were detected for genetic variants of significance in primary screening and previously reported genetic variants.
RESULTS: In primary screening stage, 13 genetic variants of ERAP1 showed an association with psoriasis. A total of 18 genetic variants were typed for the validation, and 12 genetic variants were associated with PsV in Inner Mongolia Han population. Stratified analysis showed significant differences in the allele frequencies of 8 ERAP1 genetic variants in cases with positive family history, and significant differences in allele frequencies among 9 ERAP1 genetic variants in patients with negative family history. A risk haplotype (TCCCTCCAGACC) was significantly associated with PsV, and the most risk haplotype was E730/K528/R127/E56.
CONCLUSION: ERAP1 gene mutation may be associated with PsV and HLA-C*06:02 in Han nationality in Inner Mongolia. A risk haplotype of four-nonsynonymous mutation (E730/K528/R127/E56) is associated with PsV.
PURPOSE:To separate the titled compound useful as a component of medicine, from a leguminous plant, efficiently at a low cost, by extracting a leguminous plant with an alkaline aqueous solution at room temperature, and subjecting the extract to the adsorption and elution treatments using non-polar or slightly polar adsorption resin. CONSTITUTION:At least a part of a leguminous plant is, if necessary heated in e.g. an organic solvent (e.g. n-hexane) to effect the defatting, and extracted with an alkaline aqueous solution (e.g. NaOH solution) to remove the cellulosic component. The extact liquid is optionally made acidic, and treated with non-polar or slightly polar adsorption resin. When the extract is made acidic before the treatment, the precipitate proteins are separated. The saponins and flavones adsorbed to said adsorption resin are eluted and separated by treating with a polar solvent (e.g. methanol). The eluate which is not adsorbed to the resin is if necessary subjected to the protein-removing treatment, and concentrated to obtain sugar. The treatment with the alkaline aqueous solution can be carried out at room temperature, and accordingly, the thermal energy can be saved and the product having low denaturation degree can be obtained.
PURPOSE: Pain is highly prevalent in spinal cord injury (SCI) and a key determinant of quality of life (QoL). This is the first study to examine reciprocal associations between pain and QoL in patients undergoing their first inpatient rehabilitation after SCI.
METHODS: Longitudinal data, with three measurement time points (1 month and 3 months after SCI onset, and at discharge from inpatient rehabilitation) from the Inception Cohort of the Swiss Spinal Cord Injury Cohort Study. Participants were 381 individuals aged ≥ 16 years with a newly diagnosed traumatic or non-traumatic SCI. 75.1% were male and the average age was 53.2 years. Random intercept cross-lagged panel models were conducted to examine the reciprocal association between pain intensity and QoL, as measured with the International SCI QoL Basic Data Set three individual items (satisfaction with life, physical health, and psychological health) and total score (mean of the three individual items).
RESULTS: Both item and total QoL scores increased over time. 1 month: 5.3 (SD = 2.7), 3 months: 5.9 (SD = 2.3), discharge: 6.6 (SD = 2.0). Participants reported relatively low levels of pain intensity that remained stable over the course of inpatient rehabilitation. 1 month: 2.7 (SD = 2.3), 3 months: 2.6 (SD = 2.4), discharge: 2.7 (SD = 2.5). There were no significant cross-lagged associations between QoL and pain intensity across time.
CONCLUSION: Results indicate that pain intensity does not predict changes in QoL during first rehabilitation, and vice versa. Associations between pain intensity and QoL reported by previous studies may be attributable to individual characteristics and timely events that simultaneously influence pain and QoL.
FIELD: cosmetic industry. SUBSTANCE: invention relates to agents used for treatment of keratin materials, for example, hair. Composition for treatment of keratin substances, in part, hair has grafted organosilicon polymer of polysiloxane structure with grafted silicon-free organic monomer in cosmetically or dermatologically acceptable medium and at least one aqueous dispersion of insoluble particles of nonionogenic or cationic polymer and method of hair treatment with proposed composition. Composition provides good care for hair, it shows good fixing activity and cosmetic properties, for example, distribution, stacking and fluffy of hair. EFFECT: improved properties and quality of composition, improved method of treatment. 29 cl, 2 ex
This is designed to be a double-blind, placebo-controlled, randomized study. Approximately 30 participants will be randomized, dosed and followed. Participants will be randomly assigned to receive a single intravenous (IV) dose of MEDI-557 or placebo. Participants will be inoculated with RSV-A. Participants will be followed for efficacy for 12 days post-RSV challenge. Safety follow-up will be approximately 12 months from randomization.
Systems and methods for generating synthesized images are provided. An input medical image of a patient in a first domain is received. A synthesized image in a second domain is generated from the input medical image of the patient in the first domain using a first generator. The first generator is trained based on a comparison between segmentation results of a training image in the first domain from a first segmentor and segmentation results of a synthesized training image in the second domain from a second segmentor. The synthesized training image in the second domain is generated by the first generator from the training image in the first domain. The synthesized image in the second domain is output.
Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo: Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.